CytomX Therapeutics Inc
General ticker "CTMX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $94.9M
CytomX Therapeutics Inc does not follow the US Stock Market performance with the rate: -26.1%.
Estimated limits based on current volatility of 3.5%: low 1.02$, high 1.09$
Factors to consider:
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2022-12-31 to 2024-12-30
- 2022-12-31 to 2023-12-31 estimated range: [0.90$, 2.32$]
- 2023-12-31 to 2024-12-30 estimated range: [1.14$, 2.78$]
Financial Metrics affecting the CTMX estimates:
- Negative: Non-GAAP EPS, $ of -1.51 <= 0.10
- Negative: Operating profit margin, % of -65.59 <= 1.03
- Negative: Operating cash flow per share per price, % of -51.09 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -21.66 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.17 <= 2.14
- Positive: Interest expense per share, $ of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term CTMX quotes
Long-term CTMX plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $37.31MM | $53.16MM | $101.21MM |
| Operating Expenses | $153.35MM | $154.50MM | $107.70MM |
| Operating Income | $-116.04MM | $-101.33MM | $-6.48MM |
| Non-Operating Income | $0.17MM | $2.02MM | $9.81MM |
| R&D Expense | $114.19MM | $111.65MM | $77.68MM |
| Income(Loss) | $-115.87MM | $-99.32MM | $3.32MM |
| Taxes | $0.00MM | $0.00MM | $3.89MM |
| Profit(Loss) | $-115.87MM | $-99.32MM | $-0.57MM |
| Stockholders Equity | $-0.46MM | $-85.75MM | $-47.45MM |
| Inventory | $0.00MM | $0.00MM | $0.00MM |
| Assets | $339.41MM | $260.89MM | $201.79MM |
| Operating Cash Flow | $-119.03MM | $-110.79MM | $-56.03MM |
| Capital expenditure | $1.61MM | $1.74MM | $0.84MM |
| Investing Cash Flow | $22.49MM | $98.26MM | $-150.67MM |
| Financing Cash Flow | $110.21MM | $0.65MM | $30.23MM |
| Earnings Per Share* | $-1.26 | $-1.48 | $-0.01 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.